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tients with incurable, symptomatic, solid tumors, who received new outpatient chemotherapy with pal-
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palm-based E-MOSAIC assessment (Edmonton-Symptom-Assessment-Scale, ￿3 additional symptoms, es-
timated nutritional intake, body weight change, Karnofsky Performance Status, medications for pain,
fatigue, nutrition). A cumulative, longitudinal monitoring sheet (LoMoS) was printed immediately. Eli-
gible experienced oncologists were defined as one cluster each and randomized to receive the immediate
print-out LoMoS (intervention) or not (control). Primary analysis limited to patients having unin-
terrupted (>4/6 visits with same oncologist) patient-oncologist sequences was a mixed model for the
difference in patients global quality of life (G-QoL; items 29/30 of EORTC-QlQ-c30) between baseline
(BL) and week 6. Intention-to-treat (ITT) analysis included all eligible patients. RESULTS: In 8 cen-
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symptoms (difference last study visit-BL: intervention -5.4 versus control 2.1, P = 0.003) and favored the
intervention for communication and coping. More patients with high symptom load received immediate
symptom management (chart review, nurse-patient interview) by oncologists getting the LoMoS. CON-
CLUSION: Monitoring of patient symptoms, clinical syndromes and their management clearly reduced
patients’ symptoms, but not QoL. Our results encourage the implementation of real-time monitoring in
the routine workflow of oncologist with a computer solution.
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Key message: 
Monitoring of symptoms of advanced cancer patients has little impact on patient outcomes. 
When symptoms are monitored with clinical syndromes in oncologist’s routine workflow, 
facilitated by an electronic solution, symptom control improves. Improved symptom 
management suggests behavioral changes. Real time monitoring of a combination of patient 
reported outcomes and clinical data is promising.  
 
 
Abstract 
Background:  
Patients with advanced, incurable cancer receiving anticancer treatment often experience 
multidimensional symptoms. We hypothesize that real-time monitoring of both symptoms and 
clinical syndromes will improve symptom management by oncologists and patient outcomes. 
 
Patients and Methods:  
In this prospective multicenter cluster-randomized phase-III trial patients with incurable, 
symptomatic, solid tumors, who received new outpatient chemotherapy with palliative 
intention, were eligible. Immediately before the weekly oncologists’ visit patients completed 
the palm-based E-MOSAIC assessment (Edmonton-Symptom-Assessment-Scale, ≤3 
additional symptoms, estimated nutritional intake, body weight change, Karnofsky 
Performance Status, medications for pain, fatigue, nutrition). A cumulative, longitudinal 
monitoring sheet (LoMoS) was printed immediately. Eligible experienced oncologists were 
defined as one cluster each and randomized to receive the immediate print-out LoMoS 
(intervention) or not (control). Primary analysis limited to patients having uninterrupted (>4/6 
visits with same oncologist) patient-oncologist sequences was a mixed model for the 
difference in patients global quality of life (G-QoL; items 29/30 of EORTC-QlQ-c30) between 
baseline (BL) and week 6. Intention-to-treat analysis included all eligible patients. 
 
Results 
In 8 centers, 82 oncologists treated 264 patients (median 66y; overall survival intervention 
6.3, control 5.4 mts) with various tumors. The between-arm difference in G-QoL of 102 
uninterrupted patients (intervention: 55; control: 47) was 6.8 (p=0.11) in favour of the 
intervention, in a sensitivity analysis (oncologists treating ≥2 patients; 50, 39) it was 9.0 
(p=0.07). Intention-to-treat analysis revealed improvement in symptoms (difference last study 
visit - BL: intervention -5.4 versus control 2.1, p= 0.003) and favoured the intervention for 
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communication and coping. More patients with high symptom load received immediate 
symptom management (chart review, nurse-patient interview) by oncologists getting the 
LoMoS. 
 
Conclusion 
Monitoring of patient symptoms, clinical syndromes and their management clearly reduced 
patients’ symptoms, but not QoL. Our results encourage the implementation of real-time 
monitoring in the routine workflow of oncologist with a computer solution. 
 
Key words: 
Symptom monitoring, clinical benefit, electronic assessment, decision making, integration 
oncology & palliative care, chemotherapy palliative intention 
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Introduction 
Patients with advanced, incurable cancer experience multiple, fluctuating, and 
multidimensional symptoms, many of which are under-recognized and undertreated. 
Oncologists are often the central care providers, but in different health care systems their 
professional roles may differ substantially, influenced also by availability of nurses and other 
staff.[1] Anticancer treatments for patients with advanced incurable cancer are often intended 
to stabilize or improve quality of life and alleviate symptoms Symptom control is one key 
component of palliative care.[2, 3]  
In prior studies, monitoring of symptoms (patient-reported outcomes (PROs) by use of 
computerized systems enhanced the likelihood of symptoms assessment [4] and 
communication,[5] but did not improve outcomes.[6, 7] Isolated symptom information is  
therefore not consistently used by oncologists.[8] When symptom monitoring is amended by 
nurse-delivered patient education and coaching or self-management support, distress as an 
outcome parameter could be improved.[9, 10] We added clinical data and pharmacological 
management to patient reported symptoms in order to mirror oncologists’ routine practice.  
E-MOSAIC (electronic monitoring of symptoms and syndromes associated with cancer) 
assessment was developed on a PALM device. Feasibility and reliability was reported 
previously.[11]   
The E-MOSAIC assessment was done by all patients immediately before weekly oncology 
outpatient visits using a handheld computer. A printed colored comprehensive longitudinal 
monitoring sheet (LoMoS) was immediately given to the oncologists in the intervention group.   
In this cluster-randomized controlled multicenter trial we tested the effects of the E-
MOSAIC intervention in patients with incurable cancer getting a new line of chemotherapy 
with a palliative intention.  
 
Methods 
This multicenter trial (NCT00477919) was conducted in accordance with the Declaration 
of Helsinki and the Guidelines of Good Clinical Practice issued by ICH. It was approved by 
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the local ethics committees of all centers. Patients and physicians gave written informed 
consent. 
 
Study population 
Eligible patients received anticancer treatment with palliative intent and an expected tumor 
response rate ≤ 20%, on a weekly, biweekly, or continuous schedule in the outpatient setting. 
Patients had to be clinically not cognitively impaired; symptomatic defined as at least one 
Edmonton symptom assessment score (ESAS) symptom score ≥3/10. Patients were 
characterized for age, gender, tumor type, Education (basic primary/secondary vs higher), 
Comorbidities (severe symptomatic requiring actual treatment). 
Oncologists and needed to have training in internal medicine and  ≥1 year experience in 
medical oncology which includes typically basic symptom management and were required to 
independently perform medical interventions and to have completed a communication skills 
course.  
 
Trial design 
A cluster-randomized design with the individual oncologists constituting clusters was 
applied to test the 6-weeks E-MOSAIC intervention. This design was chosen to avoid the 
potential bias of learning effects and under the assumption that physicians treat all patients 
the same. 
    At enrolment each participating physician was randomly allocated to one of the 2 arms 
at 1:1 ratio stratified according to institution using the block randomization method. 
Randomization of physicians and registration of patients was performed via fax at the SAKK 
coordinating center. 
 
Intervention 
The intervention was previously described in detail.[12] All patients were seen first by 
nurses who possibly assisted with the E-MOSAIC assessment. The LoMoS contains weekly 
cumulative quantitative information on patients’ symptoms, clinical data and medications 
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(ESAS, ≤3 additional symptoms, estimated nutritional intake, body weight change, Karnofsky 
performance status, medications for pain [daily dose of analgesics converted to oral 
morphine equivalent dose; co-analgesics], fatigue [methylphenidate, erythropoietin], and 
nutrition [oral nutritional supplements]). It was printed out immediately and delivered to the 
oncologists in the intervention arm. No specific education and no treatment guidelines were 
provided. The LoMoS was removed from the charts in order to maintain blinding. The staff 
assessing the patients was blinded to the randomization. 
 
Primary endpoint 
The primary endpoint was change in Global Quality of Life (G-QoL), measured as the 
difference in G-QoL between baseline and after last study visit (6 weeks). The change in QoL 
was assessed using the composite score of questions 29 and 30 of the EORTC-QLQ-C30. 
 
Secondary Endpoints  
The secondary endpoints: symptoms, symptom complexity, KPS, nutrition and 
oncologists’ symptom management performance were measured at baseline and then 
weekly. Communication and patient coping and treatment burden were assessed at baseline 
and at weeks 3 and 6. 
Symptoms: Symptom distress score:  The sum of the nine ESAS items as used in the 
original publication.[13] Symptom complexity was defined as ≥3 symptoms with ≥6/10, with 
the exception of fatigue and anorexia (threshold ≥9/10). Function was assessed by KPS and 
physical and emotional function scores from EORTC-QLQ-C30, Nutrition by the symptom 
appetite, patient-perceived nutritional intake and weight loss.  
To measure oncologists’ symptom management performance, all diagnostic, therapeutic 
or coordinative interventions performed by the oncologist to alleviate multidimensional 
suffering of patients and family members were collected from routine medical charts 
(Structured Chart Review, SyMPeC) [14] and by nurses asking patients about last weeks’ 
oncologists interventions (visit form). The number of visits with a symptom load above the 
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mentioned threshold without immediate oncologists’ intervention was assessed. Immediate 
intervention was defined as either ticking “yes” on the visit form or as derived by SyMPeC.  
Patients’ estimation of the patient-physician communication were assessed by a 
previously published but not specifically validated scale (80-100)[15].  The indicators for 
patients’ subjective coping effort and burden of treatment have been validated.[16, 17]. 
 
Data analysis and statistical considerations  
Half a standard deviation was chosen as a clinically meaningful difference in G-QoL 
between the study arms [18]. Assuming an overall variance of 400 an intra-cluster correlation 
coefficient (ICC) 0.05 and cluster size 12 evaluable patients per physician, 240 evaluable 
patients were needed to show the clinically relevant difference with power 0.8 and 
significance level 0.05 using a mixed model. In the interim analysis it was seen that the 
cluster sizes were smaller, thus the sample size was re-estimated with four patients per 
cluster to a total of 168 evaluable patients. To compensate for attrition it was increased to 
264 patients.  
The primary endpoint included all patients having uninterrupted visits by the same 
oncologist, defined by strict, predefined criteria such as a screening threshold of cognitive 
impairment (see Figure 1).[19] A supportive analysis was performed based on the intention-
to-treat (ITT) population, in which all eligible patients were included if the QoL data at 
baseline and at 6 months as well as the predefined covariates were available.  A sensitivity 
analysis with oncologist treating more than one patient was done. 
For the primary endpoint a priori defined covariates (education, tumor type, predominant 
symptom, anxiety, complexity, hospitalizations) and the baseline G-QoL value were included 
in the analysis model. Due to clustering structure, comparisons of different outcomes 
between treatment arms were analyzed by mixed models. All secondary endpoints were 
analyzed based on the ITT population using all available assessments for the respective 
endpoint. No imputation for missing data was performed. For endpoints with continuous 
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values, linear mixed models were applied, for endpoints with categorical or binary values, 
nonlinear mixed models or generalized estimating equations. The oncologist was included as 
random effect. All statistical tests were done two-sided at a significance level of 0.05. As no 
adjustment for multiple testing was applied for analyses other than the primary endpoint 
analysis, they were exploratory. All analyses were performed using SAS 9.2 (SAS Institute) 
and R 2.15.2 (http://www.r-project.org). 
 
Results 
Eight centers in Switzerland participated. 82 oncologists were randomized.  Between July 
2007 and January 2012 264 patients were included, median age was 66 years. In Table 1 
the patients and oncologists are characterized with respect to socio-demographic variables 
and patients’ disease and treatment-related variables. The most frequent applied 
chemotherapies were platinum compounds and taxanes, followed by pyrimidines 
(gemcitabine, 5-FU). Most often double-combination chemotherapies were used, targeted 
therapies only in few cases often in combination (Cetuximab, Bevacizumab). 
 
The patient flow is summarized in Figure 1. The median overall survival was 5.78 months 
(control: 5.39 months, intervention 6.28 months; log-rank p-value=0.9). The median follow up 
time was 3.39 months (95% confidence interval 3.22 to 3.48).   
 
Global Quality of Life 
For the primary analysis 102 (39%) patients were included. Main reasons for non-
inclusion were attrition (missing QoL measurement at week 6, 78 patients), less than 4 
physician visits (44 patients) and insufficient cognitive function (58 patients) (Figure 1).    
The standard deviation of difference in G-QoL between baseline and week 6 over all 
patients was 21.92, thus a difference between the two study arms of 10.96 was considered 
clinically meaningful. 
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The between-arm difference was 6.84 [-1.65, 15.33] (p=0.1) in favor of the intervention 
arm. The mixed model for the primary endpoint with the solution for fixed effects is displayed 
in Table 2. Of the preselected covariates only baseline G-QoL and hospitalization (p=0.09) 
had a significant effect on G-QoL (p=0.0008). The ICC could not be calculated for this model 
because of numerical problems due to the high number of physicians with only one patient. 
For the ITT analysis of 177 patients included the ICC was 0.04 and the between-arm 
difference was 5.95 [-0.20, 12.09] (p=0.06) in favor of the intervention arm. 
The sensitivity analysis with 41 oncologists (39 patients; control, 50 intervention) provided 
similar results as the original model: The between-arm difference was 8.96 [-0.88, 18.81] 
(p=0.07) in favor of the intervention arm. The ICC was 0.03. 
 
Symptoms  
The differences of symptoms and the syndromes fatigue and nutrition between baseline 
and after last study visit are listed in Table 3. 
The change in symptom distress score between first and last visit was compared between 
the two treatment arms using a linear mixed model including baseline symptom distress 
score as covariate and oncologist as random effect. There was a significant (p=0.003) 
difference of 5.70 [95% CI 1.96, 9.43] in favor of the intervention arm. 
 
Symptom Management Performance 
The difference between the arms showed a trend favoring the intervention arm (p=0.06). 
There were 71 (52%) patients in the intervention arm and 40 (38%) patients in the control 
arm, who had symptom management intervention in visits with a symptom load above a 
defined threshold. 
 
Communication, coping and treatment burden  
The differences between arms at baseline and at last study visit are displayed in Table 4 
in the supplementary material.  
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Discussion 
The E-MOSAIC intervention incorporates clinical and management data in addition to 
patient-reported symptom information into the oncologist routine workflow. The significant 
improvement in symptom distress of the overall intervention and the observed trends of 
improved symptom management, communication, and coping is promising. However, the 
hypothesized effect on global QoL was not reached. However, the hypothesized effect on 
global QoL for the strictly defined per protocol population of uninterrupted single oncologist-
patient visits was not reached. This analysis was underpowered and too ambitious. 
Therefore, the intervention may be interpreted as an intervention applicable for mid-size 
cancer centers and may limit generalizability to single oncologist practices.  
 
Our intervention showed positive effects on the specifics of the intervention (symptoms and 
symptom management). This is in line with other trials, where interventions such as end-of-
life preparation did not improve depression, but improved communication at end-of-life.[20] 
This finding reflects the concept of mechanism based interventions, rather than a complex 
intervention. 
Even though there was a clear improvement of overall symptoms, we could not identify 
specific symptoms, which were more responsive to the intervention than others, which is 
consistent with published trials. [9, 10] According to our definition, patients with more 
symptoms and higher symptom scores had higher symptom complexity. Previous 
randomized controlled trials on specialist palliative care seem also to be most effective in 
complex situations.[2, 21]. In general the symptom burden of our population is comparable 
with other symptom epidemiological data.[22]  
In daily practice it is challenging for oncologists to differentiate cancer related symptoms 
and therapy associated toxicity. Data from anticancer clinical trials usually mix toxicity and 
quality-of-life.[23]  Therefore we cannot assume that E-MOSAIC improved symptoms due to 
reduction of toxicity. The types of chemotherapy and the response rates were similar in both 
arms. 
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Limitations: 
Our results might be limited to the specific setting with weekly visits, oncologists’ 
education including palliative care and communication competences, the selected group of 
patients living half a year and flexibility of operational and financial circumstances. The study 
did not have any focused or structured patient education nor provide nurse-led symptom 
counselling or patient empowerment, and our care settings did not include routine joint 
nurse-physician visits. 
A learning effect is possible by the teams with increasing use of the E-MOSAIC and 
LoMoS data. In an attempt to prevent this, LoMoS sheets were removed from the charts.  
The lack of full blinding may limit the results. Standard care without E-MOSAIC 
assessment was not compared to the two arms. 
The number of patients in the primary analysis requiring uninterrupted sequences and 
intact cognitive function at every visit was lower than anticipated, which resulted in a loss of 
statistical power. Several physicians included only one patient. The reality of oncology clinics 
with physicians working in rotations, part-time and being on leave hindered the continuous 
care over a longer time period. However, the sensitivity analysis excluding those clusters of 
only one patient per physician confirmed the results of the primary analysis. The observed 
attrition rate of 32% in the intervention and 27% in the control arm occurs commonly in trials 
of advanced cancer patients. [24] 
Future research should focus on the questions whether provision of clinical practice 
recommendations by education, decision aids, or computer based decision support systems 
would further enhance patient care.[25] Our data may encourage a more patient-centred 
research culture.  
Our results encourage the implementation of combined monitoring of symptoms and 
related clinical parameter and medications in the routine workflows of oncologist in an 
integrated and computer interface solution (e.g. web-based, e-health record), which suggest 
also available professional or proxies patient support.[5] 
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Conclusion  
The provision of real-time combined information of advanced cancer patients’ symptoms, 
related clinical syndromes and their medication in the routine work flow of oncologists 
resulted in promising effects concerning symptoms and symptom management.  
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Legends 
 
Figure 1: CONSORT Diagram for cluster randomized trials  
 
Table 1: Patients and oncologists characterization with respect to sociodemographic 
variables and patients’ disease and treatment-related variables for each arm 
 
Table 2: Mixed model for the primary endpoint with the solution for fixed effects  
 
Table 3: ESAS, symptom, function, nutrition, complexity and symptom management 
performance   
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Table 1 Demographics of patients and oncologists 
PATIENTS 
 
Variable Control 
(N=119) 
Intervention 
(N=145) 
Gender     
.     Female 47 (39%) 51 (35%) 
.     Male 72 (61%) 94 (65%) 
Age (in years) (median, 
min, max) 
67.3 (35.3, 84.3) 65.1 (39.9, 84.3) 
Education     
.     Basic education 94 (79%) 104 (72%) 
.     Additional 
education 
24 (20%) 40 (28%) 
.     Missing 1 (1%) 1 (1%) 
Tumor type     
NSCLC 25 21% 25 17% 
Colorectal cancer 18 5% 20 14% 
Prostate carcinoma 13 11% 10 7% 
Breast cancer 12 10% 15 10% 
Pancreatic carcinoma 10 8% 20 14% 
Bladder cancer  6 5% 3 2% 
Ovarian cancer 6 5% 4 3% 
Unknown primary 
cancer 
4 3% 9 6% 
Gastric cancer 4 3% 4 3% 
SCLC extensive 
disease 
3 3% 1 1% 
Upper GI cancer 3 3% 4 3% 
Oesophageal cancer 3 3% 2 1% 
Metastatic melanoma 2 2% 2 1% 
Renal cell carcinoma 2 2% 2 1% 
Mesothelioma 2 2% 3 % 
Sarcoma 2 2% 2 1% 
Biliary tract carcinoma 1 1% 1 1% 
Glioblastoma 0 0% 2 1% 
H&N cancer 0 0% 7 5% 
Other  0 0% 4 3% 
Comorbidity1     
.     No 101 (85%) 107 (74%) 
.     Yes 16 (13%) 34 (23%) 
Oncologist 
 
Variables A 
(N=42) 
B 
(N=40) 
 n (%) n (%) 
Gender     
.     Female 13 (31%) 20 (50%) 
.     Male 29 (69%) 20 (50%) 
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Table 1 Demographics of patients and oncologists (Continued) 
 
Variable Control 
(N=119) 
Intervention 
(N=145) 
Age (in years) (median, 
min, max) 
37.0 (30, 56) 37.0 (31, 58) 
Mother  tongue      
.     French 1 (2%) 1 (3%) 
.     French and 
German 
2 (5%) 0 (0%) 
.     German 35 (83%) 35 (88%) 
.     Italian 3 (7%) 3 (8%) 
.     Romanian (Arm 
A)/English (Arm B) 
1  (2%) 1 (3%) 
1. Defined as presence of severe symptomatic comorbidity requiring actual 
treatment. 
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Table 2: Mixed model for the primary endpoint including patients having uninterrupted visits 
with the same oncologist (n=102): Solution for fixed effects 
 
Effect Categories Estimate Standard 
Error 
Confidence 
Interval  
p-value 
Randomization 
Arm 
 
 -6.9 4.2 [-15.3, 1.7] 0.1 
Baseline G-QoL  -0.6 0.1 [-0.8, -0.2]  0.001 
Predominant 
Symptom 
 
Anxiety 1.6 24.2 [-47.7, 
51.0] 
0.9 
Appetite 7.9 13.0 [-18.6, 
34.5] 
0.5 
Shortness of breath -15.5 13.7 [-43.4, 
12.4] 
0.3 
Tiredness -9.0 11.4 [-32.4, 
14.3] 
0.4 
Pain -3.8 13.3 [-31.0, 
23.3] 
0.8 
Drowsiness 7.4 21.8 [-37.0, 
51.7] 
0.7 
Wellbeing 1.4 14.2 [-27.6, 
30.3] 
0.9 
Nausea 0 . . . 
Other  -9.7 10.1 [-30.2, 
10.9] 
0.3 
Complexity 0 7.74 5.7 [-3.9, 19.4] 0.2 
1 * 0 . . . 
Anxiety 0 13.4 20.3 [-28.1, 
54.9] 
0.5 
1 ** 0 . . . 
Hospitalization 
 
No 11.3 6.4 [-1.7, 24.4] 0.09 
Yes 0 . . . 
Education Baseline education 2.7 5.1 [-7.7, 13.1] 0.6 
Additional education 0 . . . 
Tumor Type Renal cell carcinoma 46.6 18.7 [8.6, 84.6] 0.02 
Pancreatic carcinoma 14.4 14.3 [-14.7, 
43.4] 
0.3 
Mesothelioma 7.3 19.8 [-33.2, 
47.7] 
0.7 
Prostate carcinoma 17.7 13.8 [-10.4, 
45.8] 
0.2 
NSCLC 3.1 13.2 [-23.8, 
30.1] 
0.8 
Colorectal cancer 18.3 13.5 [-9.1, 45.8] 0.2 
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Table 2: Mixed model for the primary endpoint including patients having uninterrupted visits 
with the same oncologist (n=102): Solution for fixed effects (Continued) 
 
Effect Categories Estimate Standard 
Error 
Confidence 
Interval  
p-value 
Tumor Type 
(Continued) 
Upper GI cancer 26.8 16.1 [-6.0, 59.7] 0.1 
Bladder cancer 37.7 16.9 [3.2, 72.2] 0.03 
Sarcoma -2.4 19.3 [-41.8, 
37.0] 
0.9 
Unknown primary cancer 18.2 14.9 [-12.3, 
48.6] 
0.2 
Breast cancer 10.0 14.3 [-19.2, 
39.3] 
0.5 
Ovarian cancer 8.6 15.7 [-23.5, 
40.8] 
0.6 
H&N cancer 2.5 16.0 [-30.1, 
35.0] 
0.9 
Biliary tract carcinoma 30.6 23.1 [-16.6, 
77.8] 
0.2 
Gastric cancer 18.0 16.7 [-16.1, 
52.1] 
0.3 
 Esophageal cancer 4.2 18.0 [-32.5, 
40.9] 
0.8 
Other situation 0 . . . 
Intercept  -8.6 26.1 [-61.4, 
44.2] 
0.7 
* 1 defined: >=3 symptoms (of the 9 ESAS Symptoms and 1 free choice) above threshold (fatigue and 
anorexia >=9/10, other symptoms >=6/10) in baseline visit  
** 1 defined: >=6/10 in baseline visit 
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Table 3: Symptoms, Function, Nutrition, Complexity, Symptom Management Performance 
Variable 
Control 
(N=118) 
Intervention 
(N=145) 
 n median (Q1, Q3) n median (Q1, Q3) 
Symptom distress score1       
.    first visit 96 25.9 (16.9, 36.1) 112 29.0 (20.3, 39.0) 
.    last visit 96 28.7 (16.0, 41.9) 112 24.0 (12.0, 35.9) 
.    change first to last visit 96 2.1 (-7.0, 10.4) 112 -5.4 (-13.6, 3.9) 
 Difference between treatment arms2: 5.70 [95% CI 1.96, 9.43] 
Pain3       
.    first visit 96 12.8 (3.7, 31.2) 112 16.2 (5.0, 32.0) 
.    last visit 96 21.4 (5.5, 41.9) 112 11.7 (3.8, 34.2) 
.    change first to last visit 96 0.8 (-5.8, 15.9) 112 -0.5 (-8.3, 4.2) 
Fatigue3       
.    first visit 96 45.8 (22.6, 72.4) 112 38.3 (17.6, 62.2) 
.    last visit 96 39.7 (23.7, 69.3) 112 39.2 (14.4, 57.2) 
.    change first to last visit 96 0.0 (-7.4, 9.4) 112 -1.0 (-11.7, 9.6) 
Drowsiness3       
.    first visit 96 28.7 (11.9, 61.9) 112 27.3 (14.2, 49.8) 
.    last visit 96 29.3 (12.5, 57.4) 112 25.8 (8.9, 49.8) 
.    change first to last visit 96 -1.3 (-10.5, 4.9) 112 -1.0 (-12.4, 3.3) 
Nausea3       
.    first visit 96 7.1 (2.2, 16.6) 112 6.7 (1.9, 21.8) 
.    last visit 96 7.0 (2.8, 17.0) 112 6.1 (2.2, 18.3) 
.    change first to last visit 96 0.3 (-3.9, 3.1) 112 0.0 (-2.9, 2.8) 
Appetite3       
.    first visit 95 38.3 (13.9, 57.5) 112 26.9 (8.3, 51.7) 
.    last visit 96 29.7 (10.7, 59.9) 112 22.2 (4.4, 49.3) 
.    change first to last visit 95 0.0 (-12.7, 7.8) 112 -0.4 (-11.1, 4.4) 
Shortness of breath3       
.    first visit 94 12.7 (4.4, 41.1) 112 8.6 (3.2, 28.6) 
.    last visit 96 13.7 (4.9, 46.1) 111 10.6 (4.0, 28.8) 
.    change first to last visit 94 0.0 (-2.7, 7.2) 111 0.0 (-5.4, 4.4) 
Depression3       
.    first visit 96 7.8 (2.6, 16.9) 112 6.5 (2.2, 15.7) 
.    last visit 96 9.3 (3.3, 23.1) 112 5.6 (2.5, 17.2) 
.    change first to last visit 96 0.4 (-2.8, 7.9) 112 0.0 (-3.2, 2.3) 
Anxiety3       
.    first visit 96 7.3 (3.1, 17.8) 112 7.6 (2.7, 16.2) 
.    last visit 96 8.3 (3.3, 24.3) 112 6.6 (2.8, 18.3) 
.    change first to last visit 96 0.3 (-2.2, 3.9) 112 0.0 (-2.9, 2.8) 
Wellbeing3       
.    first visit 94 42.5 (22.8, 52.0) 112 30.3 (15.1, 51.8) 
.    last visit 96 35.2 (18.1, 54.5) 112 34.1 (14.2, 51.6) 
.    change first to last visit 94 0.0 (-14.3, 6.2) 112 -0.6 (-10.8, 11.8) 
Function 
KPS4 
      
.    first visit 96 75.0 (65.0, 90.0) 112 80.0 (70.0, 90.0) 
.    last visit 96 70.0 (60.0, 90.0) 112 70.0 (60.0, 90.0) 
.    change first to last visit 96 0.0 (-10.0, 5.0) 112 0.0 (-10.0, 10.0) 
 Difference between treatment arms2: 1.97 [95% CI -3.70, 7.64] 
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Table 3: Symptoms, Function, Nutrition, Complexity, Symptom Management 
Performance (Continued) 
Variable 
Control 
(N=118) 
Intervention 
(N=145) 
Function (continued)       
Physical Function5       
.    first visit 98 33.3 (20.0, 46.7) 109 33.3 (20.0, 53.3) 
.    last visit 67 33.3 (20.0, 46.7) 75 26.7 (13.3, 46.7) 
.    change first to last visit 67 0.0 (-6.7, 13.3) 75 0.0 (-13.3, 6.7) 
 Difference between treatment arms2: 5.16 [95% CI -1.46, 11.79] 
Emotional Function5       
.    first visit 99 25.0 (16.7, 50.0) 108 33.3 (16.7, 50.0) 
.    last visit 72 25.0 (8.3, 41.7) 76 25.0 (8.3, 41.7) 
.    change first to last visit 72 0.0 (-16.7, 8.3) 76 -8.3 (-16.7, 8.3) 
 Difference between treatment arms2: 4.76 [95% CI -1.09, 10.61] 
Nutrition  n median (min, max) n median (min, max) 
Weight (kg)       
.    first visit 75 68.0 (57.6, 80.0) 98 68.5 (58.0, 79.0) 
.    last visit 49 70.0 (62.0, 79.0) 55 67.0 (58.0, 78.0) 
.    change first to last visit 49 0.1 (-1.0, 1.4) 55 0.3 (-1.0, 2.0) 
 Difference between treatment arms2: 0.15 [95% CI -1.12, 1.41] 
Nutritional intake6       
.    first visit 96 3.1 (1.1, 5.2) 112 3.7 (1.3, 5.8) 
.    last visit 96 3.2 (1.2, 5.5) 111 2.3 (0.5, 4.9) 
.    change first to last visit 96 0.0 (-1.4, 1.6) 111 -0.4 (-2.5, 0.9) 
 Difference between treatment arms2: 0.68 [95% CI -0.01, 1.36] 
 n  (%) n (%) 
Symptom Complexity7       
Complexity at baseline       
.     non-complex case  80 (68%)  103 (71%) 
.     complex case  33 (28%)  40 (28%) 
.     Missing  5 (4%)  2 (1%) 
Complexity at visit 6           
.     non-complex case  65 (55%)  87 (60%) 
.     complex case   24 (20%)  17 (12% 
.     Missing  29 (25%)  41 (28%) 
 n  (%) n (%) 
Oncologist Symptom 
Management 
    
.     No visit with a symptom 
load above a defined 
threshold8 without immediate 
intervention 
40 (34%) 71 (49%) 
.     At least 1 visit with a 
symptom load above a 
defined threshold without 
immediate intervention 
66 (56%) 66 (46%) 
1) Sum ESAS  
2) Difference between treatment arms calculated using a linear mixed model including baseline as 
covariate and oncologist as random effect  
3) ESAS 0 min (no problem)-100 max (max problem)  
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4) Karnofsky Performance Scale  
5) EORTC QLQ C30 
6) Nutritional intake 0 as before disease, 10 nothing  
7) Complexity defined as ≥3 symptoms with ≥6/10, with the exception of fatigue and anorexia 
(threshold ≥9/10)  
8) Threshold defined as pain, depression, shortness of breath (≥6/10) and fatigue anorexia (≥9/10)  
Note: For theses analyses only patients with at least 4 visits were included.  
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Table 4:  Communication, Decision making preference, Coping and Burden  
Variable Control 
(N=118) 
Intervention 
(N=145) 
 n median (Q1, Q3) n median (Q1, Q3) 
Physician compassion1       
.    baseline 96 33.5 (12.0, 69.5) 129 45.0 (18.0, 91.0) 
.    week 6 77 23.0 (10.0, 61.0) 93 20.0 (10.0, 58.0) 
.    change baseline to week 6 69 -4.0 (-22.0, 10.0) 85 -14.0 (-36.0, 8.0) 
 Difference between treatment arms2: 0.80 [95% CI -16.49, 18.09] 
Physician attributes2       
Physician selfishness       
.    baseline 108 4.0 (1.0, 9.0) 138 6.0 (2.0, 11.0) 
.    week 6 84 4.0 (2.0, 9.0) 98 4.0 (2.0, 9.5) 
.    change baseline to week 6 83 0.0 (-3.0, 3.0) 95 -1.0 (-6.0, 2.0) 
Physician participation       
.    baseline 108 5.0 (2.0, 10.5) 136 7.0 (3.0, 13.0) 
.    week 6 85 4.0 (2.0, 10.0) 97 4.0 (2.0, 11.0) 
.    change baseline to week 6 84 0.0 (-3.0, 2.0) 93 -1.0 (-6.0, 2.0) 
Physician questions       
.    baseline 109 5.0 (2.0, 10.0) 136 6.0 (3.0, 11.5) 
.    week 6 85 5.0 (1.0, 9.0) 99 4.0 (2.0, 8.0) 
.    change baseline to week 6 84 0.0 (-3.0, 3.0) 94 -1.0 (-7.0, 1.0) 
Physician feelings       
.    baseline 107 5.0 (2.0, 9.0) 136 6.0 (2.5, 12.0) 
.    week 6 82 4.0 (2.0, 9.0) 98 4.0 (2.0, 9.0) 
.    change baseline to week 6 81 0.0 (-3.0, 2.0) 94 -1.0 (-7.0, 3.0) 
Physician interest       
.    baseline 108 4.0 (2.0, 8.0) 137 6.0 (2.0, 10.0) 
.    week 6 84 4.0 (2.0, 8.0) 99 4.0 (2.0, 9.0) 
.    change baseline to week 6 83 0.0 (-3.0, 3.0) 97 -1.0 (-5.0, 2.0) 
Physician relation       
.    baseline 106 4.5 (2.0, 9.0) 135 7.0 (3.0, 14.0) 
.    week 6 83 4.0 (2.0, 9.0) 98 4.0 (1.5, 11.0) 
.    change baseline to week 6 81 0.0 (-3.0, 2.0) 94 -1.0 (-7.0, 1.0) 
Physician satisfaction4       
.    baseline 88 28.0 (27.0, 32.0) 122 28.0 (27.0, 31.0) 
.    week 6 61 28.0 (27.0, 30.0) 77 28.0 (27.0, 31.0) 
.    change baseline to week 6 52 0.0 (-2.0, 2.0) 68 0.0 (-1.0, 1.5) 
 Difference between treatment arms2: -0.51 [95% CI -1.82, 0.79] 
 
Decision making preference5  
 
n % n % 
Mismatch at baseline     
.   missing 36 (31%) 31 (21%) 
.   no 38 (32%) 46 (32%) 
.   yes 44 (37%) 68 (47%) 
Mismatch at week 3     
.   missing 44 (37%) 49 (34%) 
.   no 32 (27%) 41 (28%) 
.   yes 42 (36%) 55 (38%) 
Mismatch at week 6     
.   missing 52 (44%) 66 (46%) 
.   no 32 (27%) 38 (26%) 
.   yes 34 (29%) 41 (28%) 
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Coping and Burden  
  
n median (Q1, Q3) n median (Q1, Q3) 
Coping with illness6       
.    baseline  78 33.5 (19.0, 53.0) 95 42.0 (22.0, 61.0) 
.    week 6 84 36.5 (18.0, 58.0) 95 27.0 (13.0, 47.0) 
.    change baseline- week 6 77 1.0 (-7.0, 12.0) 92 8.0 (-2.5, 21.5) 
 Difference between treatment arms2: 0.54 [95% CI 0.41, 0.67] 
Burden of treatment7       
.    baseline 78 33.5 (15.0, 55.0) 91 33.0 (14.0, 53.0) 
.    week 6 85 36.0 (21.0, 58.0) 94 29.5 (11.0, 48.0) 
.    change baseline - week 6 78 -3.0 (-15.0, 8.0) 87 1.0 (-13.0, 18.0) 
 Difference between treatment arms2: 0.52 [95% CI 0.39, 0.66] 
 
1) Patients’ estimation of physicians’ compassion (VAS, sum of 5 items, range 0-500, the lower the 
value, the better)  
2) Difference between treatment arms calculated using a linear mixed model including baseline as 
covariate and oncologist as random effect  
3) Patients’ estimation of physicians’ attributes (VAS, range 0-100, the lower the value, the better); 
4) Sum of 7 items range 1-5, total range 7-35, the higher the value, the better;  
5) Patients and physicians were assessed: 3 Categories were possible: 1)physician directed decision 
preference 2)patient-directed decision preference 3) shared decision making preference. If the 
patient’s impression and the doctor’s impression of the decision-making preferences fell into the same 
of these 3 categories, it was considered a match.  
6) Linear analogue self-assessment (LASA)) (‘no effort at all’ – ‘a great deal of effort)  
7) Overall treatment burden (‘not at all’ – ’severely’) 
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